Alpha 1a adrenergic receptor antagonist
CA 2297889 A1 · Owner: Ikemoto, Norihiro · Inventors: Roberge, Christopher M.; Li, Wenjie; Chartrain, Michel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to crystalline pharmaceutically acceptable salts of an alpha 1a adrenergic receptor antagonist Compound A, which are useful in the , treatment of benign prostatic hyperplasia. Pharmaceutical compositions employing the crystalline salts, and processes for making and using the crystalline salts and pharmaceutical compositions of Compound A are also disclosed. This invention further relates to a process for obtaining enantiomerically pure intermediate useful for the synthesis of end product alpha 1a adrenergic receptor antagonists. The end product compounds are useful for the treatment of benign prostatic hyperplasia and for relaxing lower urinary tract tissue. …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 31, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 31, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 31, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.